Trial Profile
An Open-Label, Single-Arm Phase 2 Clinical Trial Of Regorafenib in Patients With Multiply Recurrent Epithelial Ovarian Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2022
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 10 Jun 2022 Status changed from active, no longer recruiting to completed.
- 27 Apr 2021 Planned End Date changed from 1 Jun 2019 to 1 Jun 2021.
- 27 Apr 2021 Planned primary completion date changed from 1 Jun 2019 to 1 Jun 2021.